Acro Biomedical Co., Ltd.
ACBM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $60 | $6,304 | $270,189 | $250,351 |
| - Cash | $0 | $0 | $6 | $95 |
| + Debt | $27 | $52 | $26 | $50 |
| Enterprise Value | $86 | $6,356 | $270,209 | $250,306 |
| Revenue | $0 | $0 | $659 | $1,198 |
| % Growth | – | -100% | -45% | – |
| Gross Profit | $0 | $0 | $141 | $260 |
| % Margin | – | – | 21.3% | 21.7% |
| EBITDA | -$38 | $0 | -$15,870 | $0 |
| % Margin | – | – | -2,410% | 0% |
| Net Income | -$42 | -$8,808 | -$15,871 | -$7,702 |
| % Margin | – | – | -2,410.2% | -643.2% |
| EPS Diluted | -0.001 | -0.15 | -0.26 | -0.14 |
| % Growth | 99.5% | 42.3% | -85.7% | – |
| Operating Cash Flow | -$37 | -$15 | -$147 | $299 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$37 | -$15 | -$147 | $299 |